A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advancedor Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 WithoutHaving Achieved a Complete Remission

Project: Research project

Project Details

Description

A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission
StatusActive
Effective start/end date5/31/19 → 5/31/24

Funding

  • FRED HUTCHINSON CANCER CENTER
  • ALKERMES, INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint